Non-cystic Fibrosis Bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by permanent retention of mucus, dilation of bronchi, and ciliary clearance impairment. Some Clinical features include chronic daily cough, shortness of breath, sputum, and recurrent respiratory infections, with increased morbidity and worsened quality of life. One of the keystones in management of bronchiectasis is the identification & treatment of underlying causes.
DelveInsight’s ‘Non-cystic Fibrosis Bronchiectasis Pipeline Insights’ report offers exhaustive coverage of the emerging therapies in different stages of development from preclinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents.
Some of the important takeaways from the Non-cystic Fibrosis Bronchiectasis Pipeline report:
Request for Sample Page: https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
NCFB Symptoms:
The symptoms & clinical course of non-cystic fibrosis bronchiectasis are variable. Some of the patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily.
Non-cystic Fibrosis Bronchiectasis Causes
The most common cause of NCFB in the literature is post-infectious. This is not a well-defined entity, but the usual context appears to be one acute infectious episode that is thought to result in bronchiectasis. A possible mechanism for post-infectious NCFB is a significant infection in early childhood which causes structural damage to the developing lung, allowing perpetual bacterial infection. Over time, the persistent infection may then result in bronchiectasis.
Non-cystic Fibrosis Bronchiectasis Companies are:
DelveInsight’s NCFB Report covers around 5+ products under different phases of clinical development like:
Non-cystic Fibrosis Bronchiectasis Therapies are:
Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report
Coverage: Global
Key Players: Santhera Pharmaceuticals, Novartis, InsMed, Zambon, Chiesi Farmaceutici, among others.
Key Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies: Lonodelestat, Tobramycin dry-powder inhalation, INS-1007, Colistimethate sodium, CHF 6333, and others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight